In addition to chemotherapeutics, radioisotope-labeled albumin-encapsulated liposomes (e.g., 131I-labeled) have been leveraged for internal radiotherapy of 4T1 breast tumors, where a single pretreatment enhances vascular permeability and facilitates twofold greater accumulation of subsequent anti-PD-L1 and hypoxia-activated prodrug (AQ4N) therapies, improving overall survival. The gene discussed is ALB; the disease is breast neoplasm.